Henan maker of transdermal medicated patches for joint and muscle pain, a leading Chinese OTC patch brand.
Henan maker of transdermal medicated patches for joint and muscle pain, a leading Chinese OTC patch brand.
In one line: A Chinese Salonpas / Icy Hot maker.
Moat: narrow (brand, distribution). Long-established OTC patch brand with wide pharmacy shelf presence across China.
Headquarters: Xinyang, Henan, China · Employees: 2,789
Size Henan Lingrui Pharmaceutial (600285.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.04B, the 1147th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥24.11 on 18 Nov 2026.
Performance Over six months the shares gained 9.3%, against -1.3% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 4.7% over the last twelve months (peer median +11.1%); the operating margin is 22.4% (peer median 16.6%).
Valuation It trades at 15.9× forward earnings against a peer median of 23.8× (7th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 20.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.95B | CN¥3.81B | CN¥3.46B | CN¥3.28B | CN¥2.97B |
| Revenue growth | — | +10% | +5% | +10% | — |
| Gross profit | CN¥3.15B | CN¥3.01B | CN¥2.58B | CN¥2.36B | CN¥2.11B |
| EBITDA | n/a | CN¥923M | CN¥799M | CN¥670M | CN¥466M |
| Net income | CN¥827M | CN¥760M | CN¥723M | CN¥568M | CN¥465M |
| Free cash flow | CN¥1.08B | CN¥531M | CN¥781M | CN¥806M | CN¥822M |
| Capital expenditure | CN¥59.7M | CN¥56.8M | CN¥115M | CN¥21.2M | CN¥27.0M |
| Total debt | CN¥322M | CN¥437M | CN¥133M | CN¥256M | CN¥224M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Henan Lingrui Pharmaceutial 600285.SS | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% |
| Shandong Buchang Pharmaceuticals 603858.SS | $2.25B | -7% | +4% | 10% | n/a | -2.5% |
| KPC Pharmaceuticals 600422.SS | $940M | -6% | -41% | -10% | n/a | n/a |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | $3.75B | -10% | -13% | 20% | 28.5× | 16.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600285.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.8% | +0.2% | 6th highest of 21 |
| 6-month return | +9.3% | -1.3% | 8th highest of 21 |
| Distance from 52-week high | -1.4% | -28.2% | highest of 21 |
| Revenue growth (TTM) | +4.7% | +11.1% | 5th lowest of 20 |
| Operating margin | 22.4% | 16.6% | 7th highest of 19 |
| Forward P/E | 15.9× | 23.8× | 7th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -4.7% | 2.5% | 5th least demanding of 15 |
| Growth delivered (Del g) | +10.6% | +10.3% | 8th highest of 15 |
| Hurdle (Req g minus delivered) | -15.2 pp | -4.7 pp | 4th least demanding of 15 |
| ROIC minus cost of capital | +20.4 pp | -0.5 pp | 4th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| InnoCare Pharma 688428.SS | China | $2.07B | -7% | +135% | 35% | 85.7× | -10.9% | +344.2% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% | +6.5% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |